Nucleic Acid, Nucleoside, or Nucleotide – Page 5

Moderna Co-Founder Kenneth Chien’s New Biotech Secures $950M RNA Deal with Etherna

5 months ago talkbio0Tagged Chien, deal, Etherna, Kenneth, Moderna, mRNA therapies, RNA

Kenneth Chien, Moderna, Etherna, RNA deal, biotech, mRNA therapies

Intellia Therapeutics Slashes Workforce by 27% to Focus on Late-Stage CRISPR Candidates Amid Challenging Market Environment

5 months ago talkbio0Tagged Amyloidosis, Angioedema, ATTR, Clustered Regularly Interspaced Short Palindromic Repeats, Commercialization strategy, Hereditary, Intellia, Late stage, nex-z, Nexiguran, NTLA-2002, Prealbumin, Workforce

Intellia Therapeutics, CRISPR, Workforce reduction, Late-stage drug candidates, NTLA-2002, Nexiguran ziclumeran (nex-z), Hereditary angioedema, Transthyretin (ATTR) amyloidosis, Commercialization strategy

Scribe Therapeutics Prepares for Clinical Trials by Streamlining Workforce Amid Advances in Cardiometabolic Genetic Medicines

5 months ago talkbio0Tagged cardiometabolic disease, Clinical Trials, Clustered Regularly Interspaced Short Palindromic Repeats, epigenetic modification, Gene Modification

Scribe Therapeutics, cardiometabolic disease, CRISPR, gene editing, epigenetic modification, clinical trials, workforce reduction

Sanofi and Alloy Therapeutics Collaborate on CNS Drug Development Using AntiClastic Antisense Platform

5 months ago talkbio0Tagged Alloys, AntiClastic Antisense Platform, Blood - brain barrier anatomy, Clinical Nurse Specialists, Drug Development, Genetic Medicine, RNA, sanofi

Sanofi, Alloy Therapeutics, AntiClastic Antisense Platform, CNS drug development, blood-brain barrier, RNA therapeutics, genetic medicine

FDA Approves Ionis’s TRYNGOLZA for Familial Chylomicronemia Syndrome, a Rare Metabolic Disorder

6 months ago talkbio0Tagged Approved, Familial chylomicronemia syndrome, Metabolic Diseases, Olezarsen, TRYNGOLZA, United States Food and Drug Administration

FDA approval, Ionis Pharmaceuticals, TRYNGOLZA, olezarsen, familial chylomicronemia syndrome (FCS), rare metabolic disorder

Biopharma’s New Horizon: Industry Leaders Converge at JPM 2025

6 months ago talkbio0Tagged Biopharma, Biotechnology, Clustered Regularly Interspaced Short Palindromic Repeats, Doudna, Drug Industry, Gene Modification, Health care facility, healthcare, Janet, Jennifer, JPM, Robert Nelsen, Woodcock

JPM 2025, Biopharma, Jennifer Doudna, Janet Woodcock, Robert Nelsen, Scott Gottlieb, Healthcare, Gene Editing, CRISPR, Pharmaceutical Industry, Biotechnology

Editas Medicine Undergoes Major Restructuring, Cutting 65% of Staff and Halting Sickle Cell Therapy Development

6 months ago talkbio0Tagged Cell Therapy, Clustered Regularly Interspaced Short Palindromic Repeats, Editas Medicine, Gene Modification, Industry, restructuring, sickle

Editas Medicine, layoffs, restructuring, sickle cell therapy, CRISPR gene editing, biotech industry

Moderna’s RSV Vaccines Face Safety Concerns Over Severe Infections in Infants

6 months ago talkbio0Tagged Advisory Committees, concerns, Infant, Moderna, Respiratory syncytial virus, RNA, Messenger, Safety, United States Food and Drug Administration, Vaccines

Moderna, RSV vaccines, safety concerns, severe infections, infants, mRNA vaccines, FDA, advisory committee

Sarepta Therapeutics and Arrowhead Pharmaceuticals Enter $825M Global Licensing and Collaboration Agreement for Multiple siRNA Programs

7 months ago talkbio0Tagged Arrowhead, Collaboration Agreement, gene therapy, Global Licensing, Hereditary Diseases, Infrequent, Interferes with, RNA, RNA, Small Interfering

Sarepta Therapeutics, Arrowhead Pharmaceuticals, siRNA programs, Global Licensing and Collaboration Agreement, Rare genetic diseases, Gene therapy, RNA interference

Breakthrough in Heart Disease Treatment: Lilly’s Muvalaplin and Silence Therapeutics’ Zerlasiran Show Promising Results in Lowering Lipoprotein(a) Levels

7 months ago talkbio0Tagged Atherosclerosis, Cardiovascular system, Gene Silencing Therapy, Heart Disease, Interferes with, Lipoprotein(a ), Lp(a ), Muvalaplin, Risk, RNA, zerlasiran

Lipoprotein(a) (Lp(a)), Heart Disease, Muvalaplin, Zerlasiran, Cardiovascular Risk, Gene Silencing Therapy, RNA Interference, Atherosclerotic Cardiovascular Disease